SCHEMBL133634

SCHEMBL133634

COC(=O)c1ccccc1OC(=O)OCCN

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 3/20 0.55
HSD17B10 Q99714 2/20 0.50
KDM4E B2RXH2 1/20 0.50
HPGD P15428 1/20 0.50
KMT2A Q03164 3/20 0.49
HTT P42858 2/20 0.49
PRSS1 P07477 1/20 0.48
ACR P10323 1/20 0.48
MAPT P10636 2/20 0.48
ALDH1A1 P00352 1/20 0.46
CFTR P13569 1/20 0.46
ATM Q13315 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
HSP90AA1 P07900 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
SLC6A4 P31645 1/20 0.43
CTSD P07339 1/20 0.43
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22355995 0.88 SLC6A3 (0.58) SLC6A3HSD17B10KDM4EHPGDKMT2A
SCHEMBL132171 0.85 SLC6A3 (0.55) SLC6A3HSD17B10KDM4EHPGDKMT2A
SCHEMBL5706135 0.84 SLC6A3 (0.54) SLC6A3HSD17B10KDM4EHPGDKMT2A
SCHEMBL5706263 0.84 SMN1; SMN2 (0.59) SLC6A3HSD17B10KDM4EHPGDKMT2A
SCHEMBL5706062 0.84 SLC6A3 (0.54) SLC6A3HSD17B10KDM4EHPGDKMT2A
SCHEMBL4391331 0.83 SLC6A3 (0.59) SLC6A3HSD17B10KDM4EHPGDKMT2A
SCHEMBL4385197 0.83 SLC6A3 (0.59) SLC6A3HSD17B10KDM4EHPGDKMT2A
SCHEMBL15994179 0.83 SLC6A3 (0.52) SLC6A3HSD17B10KDM4EHPGDKMT2A
SCHEMBL5706195 0.83 TSHR (0.59) SLC6A3HSD17B10KDM4EHPGDKMT2A
SCHEMBL29551673 0.82 SLC6A3 (0.71) SLC6A3HSD17B10KDM4EHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420850-B2 Compounds for the synthesis of biostable polyurethane, polyurea or polyurea urethane polymers Iberhospitex, S.A (ES) 2013-04-16 US disclosed
US-8420850-B2 Compounds for the synthesis of biostable polyurethane, polyurea or polyurea urethane polymers Iberhospitex, S.A (ES) 2013-04-16 US disclosed
US-20120059117-A1 COMPOUNDS FOR THE SYNTHESIS OF BIOSTABLE POLYURETHANE, POLYUREA OR POLYUREA URETHANE POLYMERS IBERHOSPITEX, S.A. 2012-03-08 US disclosed
US-20120059117-A1 COMPOUNDS FOR THE SYNTHESIS OF BIOSTABLE POLYURETHANE, POLYUREA OR POLYUREA URETHANE POLYMERS IBERHOSPITEX, S.A. 2012-03-08 US disclosed
WO-2011141341-A1 COMPOUNDS FOR THE SYNTHESIS OF BIOSTABLE POLYURETHANE, POLYUREA OR POLYUREA URETHANE POLYMERS IBERHOSPITEX, S.A. (ES) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059117-A1 COMPOUNDS FOR THE SYNTHESIS OF BIOSTABLE POLYURETHANE, POLYUREA OR POLYUREA URETHANE POLYMERS PUF60, UMPS, UGP2 SLC6A3 2451/4885HSD17B10 4332/4885KDM4E 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.